Targeting tachykinin receptors in neuroblastoma

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Neuroblastoma, a common childhood extracranial tumor, presents a significant therapeutic challenge, particularly in high-risk cases with poor survival rates.
• Targeted therapies are crucial for improving outcomes in high-risk neuroblastoma.
• Tachykinin receptor 1 (TACR1) activation by substance P has demonstrated mitogenic effects in cancer cell lines.

Purpose of the Study:

• To investigate the expression and therapeutic potential of targeting TACR1 in neuroblastoma.
• To evaluate the efficacy of TACR1 inhibition as a novel treatment strategy for high-risk neuroblastoma.

Main Methods:

• Neuroblastoma cell lines were analyzed for TACR1 expression.
• The effects of TACR1 inhibition on cell viability and apoptosis were assessed.
• Gene expression profiling was performed to identify downstream signaling pathways.
• Preclinical studies involved treating neuroblastoma xenograft mouse models with a TACR1 antagonist (Aprepitant).

Main Results:

• Neuroblastoma cell lines express TACR1.
• Targeting TACR1 significantly reduced neuroblastoma cell viability and induced apoptosis.
• TACR1 inhibition modulated E2F2 and TP53 signaling pathways.
• Aprepitant treatment led to a significant reduction in tumor burden in vivo.

Conclusions:

• Targeted inhibition of TACR1 signaling demonstrates therapeutic efficacy in preclinical models of high-risk neuroblastoma.
• TACR1 antagonists represent a promising therapeutic avenue for improving survival in patients with high-risk neuroblastoma.